Company intelligence / Profile preview

Renalys Pharma

Ownership: Private
Development stage: Phase 3

Overview

Renalys Pharma has completed patient enrollment for its registrational Phase III clinical trial of sparsentan for IgA nephropathy in Japan. Results from the urine protein/creatinine ratio endpoint are expected in the second half of 2025[9]. The company submitted an Investigational New Drug Application for sparsentan to the PMDA in Japan in April 2024[7].

Therapeutic areas: Nephrology
Modalities: Small molecules (sparsentan)
Industry: Biotech

Drug pipeline

1 asset

sparsentan

Phase 3

Indications: IgA nephropathy

Partnerships

Travere Therapeutics (licensing agreement for sparsentan)Japan Kidney Association (collaborative agreement)[5]

Beyond the preview

Go deeper on Renalys Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Renalys Pharma.

Explore the full profile